U.S. officials report more severe allergic reactions to COVID-19 vaccines

Monday sure drop to 6.20

A Virginia woman from the Eastern region died within hours of receiving the coronavirus vaccine, according to her family.

The Virginia Department of Health said in a statement Friday that preliminary findings indicate that the cause of death was not anaphylaxis, which indicates a severe, potentially life-threatening allergic reaction. The state medical examiner is investigating the incident and officials say it may take several weeks for additional information to become available.

Up to 100 children a week are being hospitalised with a rare disease that can emerge weeks after Covid-19, leaving them in intensive care, doctors have said.

Next week rm6

Post removed.Why?

hali Target rm13 by research ???? Hahaha now days when they say that quickly sell

Rm13 target research house joke of the day.up 50c also difficult. Talking about rm13.glove play is over now is syndicate play 10 sen up sell.rss

Never ever trust research house all bullsheet

The world faces around 4,000 variants of the virus that causes COVID-19, prompting a race to improve vaccines, Britain said on Thursday, as researchers began to explore mixing doses of the Pfizer and AstraZeneca shots.

Don't talk about top glove .no point.is not going to go up,,,,just forget it

No one want to buy kossan share

no point buy glove share anymore let syndicate play themself

Q4 huge profit also no point.it won't go up.only dream.buy loos making companies share better can make more money

loss making share can go up but huge profit share cannot go up hahaha

The Covid strain spreading in the UK is now causing havoc in Australia.

Rss spoil everything

Not buying any stocks at bursa because of rss.easy money for syndicate

better dont buy anything share in bursa because of the rss

This stock is not working buying everyday down

rm20 target

my 1 sen's worth

British coronavirus variant develops new mutation linked to lower vaccine efficacy
11 cases have emerged featuring the E484 mutation, the same change seen in the South African and Brazilian strains that have caused international concern
Scientists say these infections show how border controls are not sufficient to prevent new variants from appearing in Britain
Reuters
Reuters
Published: 4:30am, 3 Feb, 2021

British coronavirus variant develops new mutation linked to lower vaccine efficacy
11 cases have emerged featuring the E484 mutation, the same change seen in the South African and Brazilian strains that have caused international concern
Scientists say these infections show how border controls are not sufficient to prevent new variants from appearing in Britain
Reuters
Reuters
Published: 4:30am, 3 Feb, 2021

A survey of residents in Shanghai, including people who are at “high risk” of contracting COVID-19, reveals that a low percentage of them are willing to take Chinese-made COVID-19 vaccines, according to a set of internal documents obtained by The Epoch Times.

The financial hub is currently experiencing a resurgence in cases, with some areas of the city going under full lockdown.

Jing’an district is one of the main urban areas of Shanghai, with roughly 1.06 million permanent residents; 39 percent of them are over the age of 60.

A set of January work reports from the Jing’an district’s health commission, which was obtained by The Epoch Times, contains survey data on locals’ willingness to take Chinese vaccines for COVID-19. Of the 113,000 people surveyed by the commission, 24,000—or roughly 21 percent—said they were willing to be vaccinated.

Meanwhile, 11,811 people in the district have already received the first dose of a COVID-19 vaccine, while 668 people have received a second dose.

While the documents don’t indicate which manufacturer’s vaccine was administered, it’s likely from the state-run drug company Sinopharm, since that’s the only one that Chinese regulators have approved for the general population.

The report also showed that 17 cases of adverse reactions were reported, including 12 cases of “general reactions,” four cases of “abnormal reactions,” and one “concidental event.” The latter term refers to an event that occurs after a vaccination but isn’t caused by the vaccine.

Officials at Sinopharm didn’t immediately respond to a request by The Epoch Times for comment.

At a Jan. 9 press conference by the central government’s State Council, officials claimed that Chinese-made COVID-19 vaccines have few health risks.

“Severe adverse reaction of vaccination occurs about one in a million.”

But based on the district’s data, out of a total of 12,479 (11,811 + 668) people, four cases of “abnormal reactions” equals to about three per 10,000.

At the same press conference, officials said vaccines will be administered in “three steps.” The first step is for “key populations,” including medical staff and personnel who work in airlines, border and customs, and logistics; the second step is to vaccinate high-risk groups, such as the elderly and people with chronic and underlying diseases; the third step is to vaccinate the general population.

But the health commission data shows that only a small number of people in the priority groups were willing to take the vaccine.

According to the data, at the Cishuixian Women and Children’s Hospital of Shanghai, only 33 people said they were willing to be vaccinated, out of 135 questioned. At the Shanghai East China Hospital, 616 people indicated a willingness, out of a total of 1,261 people surveyed. The Shanghai Dermatology Hospital found 124 people who said they were willing to be vaccinated, in a survey of 735 people.

Majority of Residents in Shanghai District Refuse to Take Chinese COVID-19 Vaccine: Govt Survey

Kossan is 1 sen up share

You buy you will regret

Buy when others are fearfully not for kosan will be more fearfully if you buy this share

Before March rm20

Tomorrow will move 1 sen in the morning

Door-to-door testing for the South Africa variant of coronavirus will take place in parts of England, after cases were found with no known links to travel or previous cases.

UK coronavir variant has mutated again

1 sen up later down 10 sen haha

Kosan is positive covid due to that cannot go up

Q below rm4 this stock play rm 4 to 4.40

haha no one intrested in this share1 sen up 10 sen down

Cannot buy this share no value , 1 sen up also it will take weeks haha

how much you buy also cannot go up

1 sen up also very diffulct,lousy stock

Nipah Virus: Scientists are concerned about "a new potential pandemic"

China’s efforts to control the recent resurgence of Covid-19 are undercutting a recovery which has been one of the bright spots in the global economy.

The first official data for January showed economic activity expanded at a much slower pace compared to December, with the services sector markedly weaker. The manufacturing purchasing managers’ index fell to 51.3, while the non-manufacturing gauge dropped to 52.4 from 55.7 in December, according to data released Sunday by the National Bureau of Statistics.

south Korea will extend social distancing restrictions imposed during its worst coronavirus spread for another two weeks, as new infections resurged last week and reversed a downward trend.

Dangerous new coronavirus strains may incubate in COVID-19’s sickest

As weeks of illness turn into months, a virus copies itself millions of times. Each copy is an opportunity to make random mistakes.

As it spins off new mutations, the virus may happen upon ones that help it resist medications, evade the immune system, and come back stronger.

By February end rm10 above

Monday above rm7

limit up

JP Morgan has put a target price of 80USD cents per share on Top Glove, who earned half a billion USD in profit after tax in one quarter!" said _Revenant_ in its post.

Monday below 50